Managing the aggressive and violent patient in the psychiatric emergency

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 4, 2006, Pages 586-598

  Rocca, Paola ^a   Villari, Vincenzo ^b   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Aggression; Antipsychotics; Benzodiazepines; Psychiatric emergency; Violence

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CLONAZEPAM; DIAZEPAM; DROPERIDOL; FLUNITRAZEPAM; HALOPERIDOL; LORAZEPAM; MIDAZOLAM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PROMETHAZINE; RISPERIDONE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

AGGRESSION; AGITATION; AKATHISIA; ANTICHOLINERGIC EFFECT; BEHAVIOR DISORDER; CLINICAL TRIAL; DECISION MAKING; DISEASE EXACERBATION; DOCTOR PATIENT RELATION; DYSTONIA; EMERGENCY HEALTH SERVICE; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; FORCE; HEART ARRHYTHMIA; HOSPITAL PERSONNEL; HUMAN; HYPOTENSION; IMMOBILIZATION; MEMORY DISORDER; PATIENT CARE; PATIENT SAFETY; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; RISK ASSESSMENT; SEDATION; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIOLENCE;

AGGRESSION; DANGEROUS BEHAVIOR; EMERGENCY SERVICES, PSYCHIATRIC; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; VIOLENCE;

EID: 33748687771     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.01.015     Document Type: Review

References (96)

1. Akiskal H.S., Azorin J.M., and Hantouche E.G. Proposed multidimensional structure of mania: beyond the euphoric-dysphoric dichotomy. J Affect Disord 73 (2003) 7-18
2. Alexander J., Tharyan P., Adams C., John T., Mol C., and Philip J. Rapid tranquillisation of agitated patients in a psychiatric emergency setting. Pragmatic randomized trial of intramuscular lorazepam versus haloperidol plus promethazine. Brit J Psychiatry 185 (2004) 63-69
3. Alexopoulos G.S., Streim J., Carpenter D., and Docherty J.P. The expert consensus guideline series. Using antipsychotics agents in older patients. J Clin Psychiatry 65 Suppl2 (2004)
4. Allen M.H. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 61 Suppl. 14 (2000) S1-S20
5. Allen M.H., Currier G.W., Hughes D.H., Reyes-Harde M., and Docherty J.P. Consensus panel for behavioral emergencies. The expert consensus guideline series. Treatment of behavioral emergencies. Postgrad Med May (Spec. No.) 1-88 (2001) 89-90 (quiz)
6. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder [revision]. Am J Psychiatry 159 Suppl. 4 (2002) Sl-S50
7. Baker R.W., Kinon B.J., Maguire G.A., Liu H., and Hill A.L. Effectiveness of rapid initial dose escalation of up to 40 mg per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 23 Suppl. 4 (2003) S342-S348
8. Baldessarini R.J., Cohen M.B., and Teicher M.H. Significance of neuroleptics dose and plasma level in the pharmacological treatment of psychosis. Arch Gen Psychiatry 45 (1988) 79-91
9. Barratt E.S., Stanford M.S., Kent T.A., and Felthous A. Neuropsychological and cognitive psychophysiological substrates of impulsive aggression. Biol Psychiatry 41 (1997) 1045-1061
10. Battaglia J., Moss S., Rush J., Kang J., Mendoza R., Leedom L., et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 15 4 (1997) 335-340
11. Benazzi F., Mazzoli M., and Rossi E. A study of intramuscolar clonazepam for psychotic agitation (letter). Can J Psychiatry 38 (1993) 70-71
12. Bieniek S.A., Ownby R.L., Penalver A., and Dominguez R.A. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy Jan-18 l (1998) 57-62
13. Blair R.J.R. A neurocognitive model of the psychopathic individual. Disorders of Brain and Mind vol. 2 (2003), Cambridge 400-417
14. Bradwejn J., Shriqui C., Koszycki D., and Meterissian G. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacology 10 (1990) 403-408
15. Brieden T., Ujeyl M., and Naber D. Psychopharmacological treatment of aggression in schizophrenic patients. Pharmachopsychiatry 35 (2003) 83-89
16. Brodaty H., and Low L.F. Aggression in the elderly. J Clin Psychiatry 64 Suppl. 4 (2003) 36-43
17. Buckley P.F., Noffsinger G., Smith D.A., Hrouda D.R., and Knoll J.L. Treatment of the psychotic patient who is violent. Psychiatr Clin North Am 26 (2003) 23l-272
18. Buss A.H., and Durkee A. An inventory for assessing different kinds of hostility. J Consult Psychol 21 (1957) 343-349
19. Chambers R.A., and Druss B.G. Droperidol: efficacy and side effects in psychiatric emergencies. J Clin Psychiatry 60 (1999) 664-667
20. Chouinard G., Safadi G., and Beauclair L. A double blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 14 (1994) 377-384
21. Citrome L. New treatments for agitation. Psychiatr Q 75 3 (2004) 197-213
22. Currier G.W., and Allen M.H. Physical and chemical restraint in the psychiatric emergency service. Psychiatr Serv 51 (2000) 717-719
23. Currier G.W., and Simpson G.M. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 62 (2001) 153-157
24. Currier G.W., Chou J.C.-Y., Feifel D., Bossie C.A., Turkoz I., Mahmoud R.A., et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 65 (2004) 386-394
25. Daniel D., Brook S., and Benattia I. Transition from IM to oral ziprasidone: clinical efficacy and safety data. Presented at the XXIIIfd Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), Montreal, Canada, June (2002) 23-27
26. Davidson R.J., Putnam K.M., and Larson C.L. Dysfunction in the neural circuitry of emotion regulation-a possible prelude to violence. Science 289 (2000) 591-594
27. Derogatis L.R., Covi L., Lipman R.S., and Rickels K. Dimensions of outpatient neurotic pathology: comparison of a clinical vs. empirical assessment. J Consult Clin Psychol 34 (1970) 164-171
28. Dorevitch A., Katz N., Zemishlany Z., Aizenberg D., and Weizman A. Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 156 (1999) 142-144
29. Duff G, 2004. Atypical antipsychotic drugs and stroke: message from Professor Gordon Duff, Chairman, Committee on Safety of Medicines (CEM/CM0/2004/1) www.mca.gov.uk/ourwork/monitorsafequalmed/safetymessages/antipsystroke_9 304.htm (accessed 15 Nov 2004).
30. Edwards R., Stephenson U., and Flewett T. Clonazepam in acute mania: a double-blind trial. Aust N Z J Psychiatry 25 (1991) 238-242
31. Expert Consensus Guidelines Series: Treatment of Schizophrenia. J Clin Psychiatry 60 Suppl 11 (1999) Sl-S80
32. Fenton M., Cuotinho E.S.F., and Campbell C. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses (Cochrane Review). Cochrane Libr Issue 1 (2002) [Oxford]
33. Filley C.M., Price B.H., Nell V., Antoinette T., Morgan A.S., Bresnahan J.F., et al. Toward an understanding of violence: neurobehavioral aspects of unwarranted physical aggression: Aspen Neurobehavioral Conference Consensus Statement. Neuropsychiatr Neuropsychol Behav Neurol 14 (2001) 1-14
34. Fisher W.A. Restraint and seclusion: a review of literature. Am J Psychiatry 151 (1994) 1584-1591
35. Foster S., Kessel J., Berman M.E., and Simpson G.M. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 12 (1997) 175-179
36. Garza-Trevino E.S., Hollister L.E., Overall J.E., and Alexander W.F. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 146 (1989) 1598-1601
37. Gerson S., and Bassuk E. Psychiatric emergencies: an overview. Am J Psychiatry 137 (1980) 1-11
38. Gill S.S., Rochon P.A., Herrmann N., Lee P.E., Sykora K., Gunraj N., et al. Atypical antipsychotics drugs and risk of ischaemic stroke: population besed retrospective cohort study. BMJ 330 (2005) 445-450
39. * (risperidone) and cerbrovascular adverse events in placebo-controlled dementia trials-Janssen-Ortho. www.hc-sc.gc.ca/hnfb-dgpsa/tpd-dpt/risperdall_e.html (accessed 15 Nov 2004).
40. Health Care Financing Administration. 2000.Hospital conditions of participation for Patients Rights: Interpretative Guidelines (available at http://www.hcfa.gov/quality/4bl.htm).
41. Hiday V. Understanding the connection between mental illness and violence. Int J Law Psychiatry 20 (1997) 399-417
42. Hovens J.E., Dries P.J., Melman C.T., Wapenaar R.J., and Loonen A.J. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. J Psychopharmacol 19 1 (2005) 51-57
43. Hughes D.H., and Kleespies P.M. Treating aggression in the psychiatric emergency service. J Clin Psychiatry 64 Suppl 4 (2003) S1-S15
44. Humble F., and Berk M. Pharmacological management of aggression and violence. Hum Psychopharmacol Clin 18 (2003) 423-436
45. Joint Commission on Healthcare Accreditation. 2002. Hospital accreditation standards. Oakbrook Terrace, IL: Joint Commission Resource; 2002 (available at http://www.jcaho.org).
46. Jones B., Taylor C.C., and Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry 62 Suppl 2 (2001) S22-S24
47. Kane J.M., Leucht S., Carpenter D., and Docherty J.P. The Expert Consensus Guideline Series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 64 Suppl. 12 (2003)
48. Kapur S., Arenovich T., Agid O., Zipursky R., Lindborg S., and Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 162 5 (2005) 939-946
49. Kay S.R., Opler L.A., and Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
50. Kay S.R., Wolkenfeld F., and Murrill L.M. Profiles of Aggression among Psychiatric Patients. J Nerv Ment Dis 176 (1988) 539-546
51. Krakowski M. Violence and serotonin: influence of impulse control, affect regulation, and social functioning. J Neuropsychiatr Clin Neurosci 15 3 (2003) 294-305
52. Lawlor B.A. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. J Clin Psychiatry 65 Suppl. 1 (2004) 5-10
53. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161 Suppl 2 (2004) S1-S56
54. Lejeune J., Larmo I., Chrzanowski W., Witte R., Karavatos A., Schreiner A., et al. Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. Int Clin Psychopharmacol 19 5 (2004) 259-269
55. Lenox R.H., Newhouse P.A., Creelman W.L., and Whitacker T.M. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 53 (1992) 47-52
56. Lesch K.P., and Merschdorf U. Impulsivity, aggression, and serotonin: a molecular psychobiological perspective. Behav Sci Law 18 (2000) 581-604
57. Lesem M.D., Zajecka J.M., Swift R.H., Reeves K.R., and Harrigan E.P. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 62 (2001) 12-18
58. Lindenmayer J.P., Brown E., Baker R.W., Schuh L.W., Shao L., Tohen M., et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res 68 (2004) 331-337
59. Lindenmayer J.P., Crowner M., and Cosgrove V. Emergency Treatment of Agitation and Aggression. In: Allen M.H. (Ed). Emergency Psychiatry (2002), American Psychiatric Press, Washington, DC 115-149
60. Man P.L., and Chen C.H. Rapid tranquilization of acutely psychotic patients with intramuscular haloperidol and chlorpromazine. Psychosomatics 4 (1973) 59-63
61. McAllister-Williams R.H., and Ferrier I.N. Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. Brit J Psychiatry 179 (2001) 485-489
62. Meehan K., Zhang F., David S., Tohen M., Janikac P., Small J., et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 21 (2001) 389-397
63. Meehan KM., Wang H., David S.R., Nisivoccia J.R., Jones B., Beasley Jr. C.M., et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 26 (2002) 494-504
64. Mendelowitz A.J. The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Ann Clin Psychiatry 16 3 (2004) 145-154
65. Mendoza R., Djenderedjian A.H., Adams J., and Ananth J. Midazolam in acute psychotic patients with hyperarousal. J Clin Psychiatry 48 (1987) 291-292
66. Moeller F.G., Barrat E.S., Dougherty D.M., Schmitz J.M., and Swann A.C. Am J Psychiatry 158 (2001) 1783-1793
67. Nestor P.G. Mental disorder and violence: personality dimensions and clinical features. Am J Psychiatry 159 (2002) 1973-1978
68. Nobay F., Simon B.C., Levitt M.A., Dresden D.O., and Dresden G.M. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med 11 (2004) 744-749
69. Parks J. Violence. In: Hillard J.R. (Ed). Manual of Clinical Emergency Psychiatry (1990), American Psychiatric Press, Washington, DC 147-160
70. Petit J.R. Handbook of Emergency Psychiatry (2004), Lippincott Williams and Wilkins, Philadelphia
71. Pilowsky L.S., Ring H., Shine P.J., Battersby M., and Lader M. Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital. Brit J Psychiatry 160 (1992) 831-835
72. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60 7 (2003) 681-690
73. Raine A., Lencz T., Bihrle S., LaCasse L., and Colletti P. Reduced prefrontal gray matter volume and reduced autonomic activity in antisocial personality disorder. Arch Gen Psychiatry 57 (2000) 119-127
74. Ramoska E.A., Linkenheimer R., and Glasgow C. Midazolam use in the emergency department. J Emerg Med 9 (1991) 247-251
75. Richards J.R., Derlet R.W., and Duncan D.R. Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med 16 (1998) 567-573
76. Rosenberg R.C., and Sulkowicz K.J. Psychosocial Interventions in the Psychiatric Emergency Service. In: Allen M.H. (Ed). Emergency Psychiatry (2002), American Psychiatric Press, Washington, DC 151-183
77. Salzman C., Solomon D., Miyawaki E., Glassman R., Rood L., Flowers E., et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 52 (1991) 177-180
78. Schneider L.S., Pollock V.E., and Lyness S.A. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 38 (1990) 553-563
79. Shale J.H., Shale C.M., and Mastin W.D. A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. J Clin Psychiatry 64 (2003) 500-505
80. Simpson D., and Anderson I. Rapid tranquillisation: a questionnaire survey of practice. Psychiatr Bull 20 (1996) 149-152
81. Steadman H.J., Mulvey E.P., Monahan J., Robbins P.C., Appelbaum P.S., Grisso T., et al. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch Gen Psychiatry 55 (1998) 393-401
82. Swann A.C. Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry 64 Suppl 4 (2003) S26-S35
83. Swanson J., Holzer C.E., Ganju V., and Jono R. Violence and psychiatric disorder in the community: evidence from the Epidemiological Catchment Area surveys. Hosp Comm Psychiatry 41 (1990) 761-770
84. Tariot P.N., Profenno L.A., and Saleem Ismail M. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 65 Suppl. 1 (2004) 11-15
85. Taylor P.J., Leese M., Williams D., Butwell M., Daly R., and Larkin E. Mental disorder and violence: a special (high security) hospital study. Brit J Psychiatry 172 (1998) 218-226
86. Thomas H., Schwartz E., and Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med 21 (1992) 407-413
87. Thornley B., Adams C.E., and Awad G. Chlorpromazine versus placebo for schizophrenia (Cochrane Review). Cochrane Libr Issue 1 (2002) [Oxford]
88. TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomized trial of midazolam versus haloperidol plus promethazine. BMJ 327 (2003) 708-711
89. Tulloch K.J., and Zed P.J. Intramuscular olanzapine in the management of acute agitation. Arm Pharmacother 38 12 (2004) 2128-2135 [Epub 2004 Nov 2. Review]
90. US FDA, 2004. 2003 Safety alert: RISPERDAL (risperidone). Washington, DC: US Food and Drug Administration; 1 Mar 2004. www.fda.gov/medwatch/SAFETY/2003/risperdal.htm (accessed 15 Nov 2004).
91. Vitiello B., and Stoff D.M. Subtypes of aggression and their relevance to child psychiatry. J Am Acad Child Adolesc Psychiatry 36 (1997) 307-315
92. Volawka J. The Neurobiology of Violence (1995), Am. Psych. Press, Washington, DC, USA
93. Webster's Third New International Dictionary of the English Language Unabridged, 1993. Konemamr.
94. Wyant M., Diamond B.I., O'Neal E., Sloan A., and Borison R.L. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol Bull 26 (1990) 126-129
95. Yildiz A., Sachs G.S., and Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 20 4 (2003) 339-346
96. Yudofsky S.C., Silver J.M., Jackson W., and Endicott J. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 143 (1986) 35-39